This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hinkle, A M
Right arrow Articles by Bodey, G P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hinkle, A M
Right arrow Articles by Bodey, G P

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1980 October; 18(4): 574-578

In vitro evaluation of Ro 13-9904.

A M Hinkle and G P Bodey

ABSTRACT

The in vitro activity of a new investigational cephalosporin, Ro 13-9904, was compared with those of four cephalosporins (cephalothin, cefamandole, cefoxitin, and moxalactam), five semisynthetic penicillins (mezlocillin, piperacillin, carbenicillin, ticarcillin, and azlocillin), and the aminoglycoside tobramycin. Ro 13-9904 inhibited 75% of all isolates of Enterobacteriaceae at a concentration of 6.25 micrograms/ml, including Enterobacter spp., Serratia marcescens, and indole-positive Proteus spp. Ro 13-9904 was only minimally active against Pseudomonas aeruginosa and enterococci. There was no significant change (greater than or equal to 2 dilutions) in drug activity when tested in various pH and media. A significant inoculum effect occurred when the size of the inoculum was increased from a concentration of 10(5) to 10(7) organisms per ml.


Antimicrob Agents Chemother. 1980 October; 18(4): 574-578




This article has been cited by other articles:

  • Baumgartner, J.-D., Glauser, M. P. (1983). Single Daily Dose Treatment of Severe Refractory Infections With Ceftriaxone: Cost Savings and Possible Parenteral Outpatient Treatment. Arch Intern Med 143: 1868-1873 [Abstract]